Ligang Xing

机构：Guizhou University, Affiliated Hospital of Southwest Medical University, Shandong Tumor Hospital, Shandong First Medical University · ORCID：0000-0002-9146-3048

发表论文 67 篇 · 总被引 1090 次 · h-index 19

代表论文

• Functional status and spatial architecture of tumor-infiltrating CD8+ T cells are associated with lymph node metastases in non-small cell lung cancer (2023 · Journal of Translational Medicine · 被引 35)
• Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial (2025 · Nature Medicine · 被引 30)
• ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC). (2024 · Journal of Clinical Oncology · 被引 24)
• Spatial features of specific CD103+CD8+ tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer (2024 · Journal of Translational Medicine · 被引 23)
• 65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC (2024 · Immuno-Oncology Technology · 被引 22)
• Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors. (2024 · Journal of Clinical Oncology · 被引 22)